Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2016Next earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 7 min agoDividend
Analysts recommendations
Institutional Ownership
APVO Latest News
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Aptevo's stock drops following the issuance of additional shares at a discounted price, resulting in a significant dilution of existing shareholders.
Aptevo Therapeutics (NASDAQ: APVO) shares are declining today following the announcement of a public offering in which the company will sell 3.4 million shares of APVO stock at $1.35 per share.
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany. Details of the Company's presentation, which will highlight its pipeline of clinical and pre-clinical bispecific drug candidates designed to fight both solid and hematologic malignancies, are as follows: Date & Time: Tuesday, November 7, 2023 @ 1:15 CET (8:15 Eastern time) Location: Trade Fair Center Messe München, San Sabastian Room, Munich, Germany Presenter: Michelle Nelson, Ph.D.
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.
What type of business is Aptevo Therapeutics?
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
What sector is Aptevo Therapeutics in?
Aptevo Therapeutics is in the Healthcare sector
What industry is Aptevo Therapeutics in?
Aptevo Therapeutics is in the Biotechnology industry
What country is Aptevo Therapeutics from?
Aptevo Therapeutics is headquartered in United States
When did Aptevo Therapeutics go public?
Aptevo Therapeutics initial public offering (IPO) was on 20 July 2016
What is Aptevo Therapeutics website?
https://www.aptevotherapeutics.com
Is Aptevo Therapeutics in the S&P 500?
No, Aptevo Therapeutics is not included in the S&P 500 index
Is Aptevo Therapeutics in the NASDAQ 100?
No, Aptevo Therapeutics is not included in the NASDAQ 100 index
Is Aptevo Therapeutics in the Dow Jones?
No, Aptevo Therapeutics is not included in the Dow Jones index
When does Aptevo Therapeutics report earnings?
The next expected earnings date for Aptevo Therapeutics is 09 August 2024